A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2011
11/23/2011	CN102247605A Antiviral effect of novel pathogen recognition molecule
11/23/2011	CN102247603A Method for promoting epidermal growth factor transdermal drug delivery of protein drug
11/23/2011	CN102247592A Novel application of ubiquitin-like modified protein in resisting virus
11/23/2011	CN102247591A Treatment of inflammatory bowel diseases with mammal beta defensins
11/23/2011	CN102247590A Drug composition for preventing or treating HIV (human immunodeficiency virus) infection and application thereof
11/23/2011	CN102247589A Application of marine collagen peptide in preparing medicament and food for delaying skin aging
11/23/2011	CN102247327A Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
11/23/2011	CN102247319A Thymalfasin-containing medicinal composition and preparation method thereof
11/23/2011	CN101647998B New use of astragalus mongolicus lectin
11/23/2011	CN101460159B Fatigue-reducing agent
11/22/2011	USRE42954 Method for repairing a defect in an intervertebral disc
11/22/2011	US8063263 Methods for the treatment or prevention of scars and/or keloids
11/22/2011	US8063191 Polynucleotides encoding for fusion proteins with natriuresis activity
11/22/2011	US8063183 Ephrin extracellular domain polypeptides for use in diagnosis prevention and treatment of cell proliferative disorders
11/22/2011	US8063182 Human TNF receptor fusion protein
11/22/2011	US8063181 Method for the production of cyclic molecules
11/22/2011	US8063179 Carbon nanotube binding peptides
11/22/2011	US8063178 Phage displayed Trp cage ligands
11/22/2011	US8063106 ApoE mimetic agents
11/22/2011	US8063056 Anti-cancer cyclopenta [g]quinazonline compounds
11/22/2011	US8063020 Resuscitation fluid
11/22/2011	US8063019 Scaffold polypeptides for heterologous peptide display
11/22/2011	US8063018 Bivalent thrombin binding molecules comprising linkers
11/22/2011	US8063017 Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products
11/22/2011	US8063016 Retro-inverso peptides derived from interleukin-6
11/22/2011	US8063014 Self-assembly of peptide-amphiphile nanofibers under physiological conditions
11/22/2011	US8063013 Method of treating glaucoma comprising administering a composition comprising human BMP7
11/22/2011	US8063011 Prediction and prophylactic treatment of type 1 diabetes
11/22/2011	US8062906 B-lymphocyte stimulator binding polypeptides and methods based thereon
11/22/2011	US8062881 Method for making a polymer blend for reducing protein binding to surfaces
11/22/2011	US8062851 FIAT nucleic acids and proteins and uses thereof
11/22/2011	US8062663 Methods and compostions for enhancing transdermal drug delivery
11/22/2011	US8062652 Compositions and methods for treating precocious puberty
11/22/2011	US8062643 Use of neurotoxin therapy for treatment of urologic and related disorders
11/22/2011	US8062634 Methods of treating cutaneous ulcers and grafts using agonist antibodies to IL-23 receptor
11/22/2011	CA2547873C Tetrapeptide regulating blood glucose level in diabetes mellitus
11/22/2011	CA2515088C Methods for the purification of stable radioiodine conjugates
11/22/2011	CA2513655C Use of tryptanthrin compounds for immune potentiation
11/22/2011	CA2494762C Pharmaceutical compositions comprising cyclosporin for oral administration
11/22/2011	CA2474106C A process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent
11/22/2011	CA2473874C A composition for treating neurocerebrovascular disorders
11/22/2011	CA2456025C An implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
11/22/2011	CA2455392C Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
11/22/2011	CA2444278C Modified cyclosporine which can be used as a pro-drug and use thereof
11/22/2011	CA2416808C Derivatives of branched-chain lipophilic molecules and uses thereof
11/22/2011	CA2372511C Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/22/2011	CA2276534C Recombinant fusion proteins based on ribosome-inactivating proteins of the mistletoe viscum album
11/22/2011	CA2258518C Recognition molecules interacting specifically with the active site or cleft of a target molecule
11/17/2011	WO2011143562A2 Il-1 binding proteins
11/17/2011	WO2011143559A2 Compositions and methods which modulate g-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
11/17/2011	WO2011143534A1 Methods for the treatment of psychiatric disorders
11/17/2011	WO2011143482A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
11/17/2011	WO2011143421A1 Insulin with a stable basal release profile
11/17/2011	WO2011143406A2 Parathyroid hormone analogs and uses thereof
11/17/2011	WO2011143362A1 Dimeric oxidation-resistant apolipoprotein a1 variants
11/17/2011	WO2011143335A2 Methods for treatment or prophylaxis of kidney or liver dysfunction
11/17/2011	WO2011143317A2 Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
11/17/2011	WO2011143209A1 Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
11/17/2011	WO2011143208A1 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
11/17/2011	WO2011143187A2 Lactoferrin -based biomaterials for tissue regeneration and drug delivery
11/17/2011	WO2011143152A2 Acth for treatment of amyotrophic lateral sclerosis
11/17/2011	WO2011142858A2 Chlorotoxin variants, conjugates, and methods for their use
11/17/2011	WO2011142843A1 Method for identifying increased risk of anxiety disorders
11/17/2011	WO2011142783A2 Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
11/17/2011	WO2011142744A1 Compositions and methods for the treatment and prevention of cardiac ischemic injury
11/17/2011	WO2011142465A1 Novel protein and use thereof
11/17/2011	WO2011141891A1 Use of cycloundecadepsipeptide compounds
11/17/2011	WO2011141820A1 Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
11/17/2011	WO2011141787A1 Use of interferon alpha for the treatment of chronic kidney disease
11/17/2011	WO2011141658A1 Peptides with antiprotease activity
11/17/2011	WO2011141407A1 Process for the preparation of insulin-zinc complexes
11/17/2011	WO2011141188A1 Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
11/17/2011	WO2011140984A1 Anti-hbv polypeptide, pharmaceutical composition and use thereof
11/17/2011	WO2011140639A1 Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion
11/17/2011	WO2011140638A1 Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
11/17/2011	WO2011140608A1 Neuropsychopharmacological treatment regimes for treating psychological disorders
11/17/2011	WO2011140607A1 A method of treatment and diagnosis
11/17/2011	WO2011127405A9 Methods and compositions for enhanced delivery of compounds
11/17/2011	WO2011115651A3 Natural plant products for control of cancer metastasis
11/17/2011	WO2011113048A3 Modulation of cytokine signaling
11/17/2011	WO2011091319A3 Dendritic cell vaccines
11/17/2011	WO2011091000A3 Oral care compositions and methods
11/17/2011	WO2011088272A9 Selective ampd2 inhibitors and methods for using the same
11/17/2011	WO2011088196A3 Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
11/17/2011	WO2011083483A3 Method for treatment of inflammatory disease and disorder
11/17/2011	WO2011081465A3 Pharmaceutical composition for suppression of vascularization
11/17/2011	WO2011077133A3 Method of treatment and screening method
11/17/2011	WO2011074881A3 Substances for inhibiting expression of genes for sensitivity to allergic disorders
11/17/2011	WO2011071968A3 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
11/17/2011	WO2011071916A3 Sr-bi as a predictor of human female infertility and responsiveness to treatment
11/17/2011	WO2011071904A3 Inhibiting bacterial infection and biofilm formation
11/17/2011	WO2011063161A3 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
11/17/2011	WO2011057243A3 Administration of plant expressed oral tolerance agents
11/17/2011	WO2011019763A3 Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
11/17/2011	WO2010136562A3 Moraxella catarrhalis antigens
11/17/2011	US20110283375 Transgenic Prothrombin And Related Thrombin Precursors And Transgenics, Methods, Compositions, Uses And The Like Relating Thereto
11/17/2011	US20110282464 Reactive Surgical Implants
11/17/2011	US20110282267 Fibroblast growth factor-9 promotes hair follicle regeneration after wounding
11/17/2011	US20110282037 Antibody preparation
11/17/2011	US20110281931 Rna sequence-specific mediators of rna interference

1 ... 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 ... 3163